Bayer AG and Nextrna Therapeutics Inc. have entered into a collaboration and license agreement to develop small-molecule therapeutics targeting long noncoding RNAs (lncRNAs) in oncology. Under the ...
TEL AVIV, Israel and OSLO, Norway, Sept. 29, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in ...
Hdy-7 directly binds to TrxR1/2, triggering ROS accumulation and p53 activation. Activated p53 negatively regulates mTORC1 signaling, which is one of the major kinases responsible for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback